Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial. (Q35867681)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26661397%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26661397%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

Antonia Morita Iswari Saktiawati

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26661397%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Tjip S van der Werf

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26661397%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

3

Ymkje Stienstra

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26661397%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Marieke G G Sturkenboom

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26661397%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Yanri W Subronto

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26661397%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Sumardi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26661397%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Jos G W Kosterink

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26661397%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Jan-Willem C Alffenaar

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26661397%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

language of work or name

English

0 references

publication date

11 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26661397%20AND%20SRC:MED&resulttype=core&format=json

Journal of Antimicrobial Chemotherapy

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26661397%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

71

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26661397%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26661397%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

703-710

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26661397%20AND%20SRC:MED&resulttype=core&format=json

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Factors associated with death during tuberculosis treatment of patients co-infected with HIV at the Yaoundé Central Hospital, Cameroon: an 8-year hospital-based retrospective cohort study (2006-2013).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Serum drug concentrations predictive of pulmonary tuberculosis outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Effect of meals on rifampicin absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Impact of food intake on the pharmacokinetics of first-line antituberculosis drugs in Taiwanese tuberculosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Rifampicin kinetics in undernutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography-tandem mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Troubleshooting carry-over of LC-MS/MS method for rifampicin, clarithromycin and metabolites in human plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Biowaiver monographs for immediate release solid oral dosage forms: ethambutol dihydrochloride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Clinical pharmacokinetics of the antituberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Population pharmacokinetics of ethambutol in South African tuberculosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Dried blood spots: a new tool for tuberculosis treatment optimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

A four-month gatifloxacin-containing regimen for treating tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV394

21 January 2018

Identifiers

DOI

10.1093/JAC/DKV394

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26661397%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference